Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jul 12;16(7):995.
doi: 10.3390/ph16070995.

Rationale for Prostate-Specific-Membrane-Antigen-Targeted Radionuclide Theranostic Applied to Metastatic Clear Cell Renal Carcinoma

Anne Laure Giraudet  1 , Armelle Vinceneux  1 , Valentin Pretet  1 , Emilie Paquet  1 , Alicia Sanchez Lajusticia  1 , Fouzi Khayi  1 , Jean Noël Badel  1 , Helen Boyle  1 , Aude Flechon  1 , David Kryza  2   3
Affiliations
Review

Rationale for Prostate-Specific-Membrane-Antigen-Targeted Radionuclide Theranostic Applied to Metastatic Clear Cell Renal Carcinoma

Anne Laure Giraudet et al. Pharmaceuticals (Basel). .

Abstract

Prostate-specific membrane antigen (PSMA), whose high expression has been demonstrated in metastatic aggressive prostate adenocarcinoma, is also highly expressed in the neovessels of various solid tumors, including clear cell renal cell carcinoma (ccRCC). In the VISION phase III clinical trial, PSMA-targeted radioligand therapy (PRLT) with lutetium 177 demonstrated a 4-month overall survival OS benefit compared to the best standard of care in heavily pretreated metastatic prostate cancer. Despite the improvement in the management of metastatic clear cell renal cell carcinoma (mccRCC) with antiangiogenic tyrosine kinase inhibitor (TKI) and immunotherapy, there is still a need for new treatments for patients who progress despite these drugs. In this study, we discuss the rationale of PRLT applied to the treavtment of mccRCC.

Keywords: PSMA; metastatic clear cell renal carcinoma; radionuclide therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Physiological PSMA expression in normal tissues assessed by [68Ga]Ga-PSMA-11 PET performed at Lumen nuclear medicine department.
Figure 2
Figure 2
Pathophysiological mechanisms of main radiopharmaceuticals used in ccRCC investigation.
See this image and copyright information in PMC

References

    1. Bukavina L., Bensalah K., Bray F., Carlo M., Challacombe B., Karam J.A., Kassouf W., Mitchell T., Montironi R., O’Brien T., et al. Epidemiology of Renal Cell Carcinoma: 2022 Update. Eur. Urol. 2022;82:529–542. doi: 10.1016/j.eururo.2022.08.019. - DOI - PubMed
    1. Feng X., Zhang L., Tu W., Cang S. Frequency, incidence and survival outcomes of clear cell renal cell carcinoma in the United States from 1973 to 2014: A SEER-based analysis. Medicine. 2019;98:e16684. doi: 10.1097/MD.0000000000016684. - DOI - PMC - PubMed
    1. Albiges L., Tannir N.M., Burotto M., McDermott D., Plimack E.R., Barthélémy P., Porta C., Powles T., Donskov F., George S., et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: Extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open. 2020;5:e001079. doi: 10.1136/esmoopen-2020-001079. - DOI - PMC - PubMed
    1. Nocera L., Karakiewicz P.I., Wenzel M., Tian Z., Shariat S.F., Saad F., Chun F.K.H., Briganti A., Kapoor A., Lalani A.K. Clinical Outcomes and Adverse Events after First-Line Treatment in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis. J. Urol. 2022;207:16–24. doi: 10.1097/JU.0000000000002252. - DOI - PubMed
    1. Choueiri T.K., Powles T., Burotto M., Escudier B., Bourlon M.T., Zurawski B., Oyervides Juárez V.M., Hsieh J.J., Basso U., Shah A.Y., et al. Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N. Engl. J. Med. 2021;384:829–841. doi: 10.1056/NEJMoa2026982. - DOI - PMC - PubMed

LinkOut - more resources